Search
for
Sort by
Research 151–180 of 287
- Methotrexate treatment of generalized granuloma annulare: a retrospective case series
- The metabolically protective energy expenditure increase of<i>Pik3r1</i>-related insulin resistance is not explained by Ucp1-mediated thermogenesis
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- TRPA1 Modulates Mechanotransduction in Cutaneous Sensory Neurons
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity
- Novel lysophosphoplipid receptors: their structure and function
- Budesonide for maintenance of remission in Crohn's disease
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Fibroblast state switching orchestrates dermal maturation and wound healing
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
- Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
- Alopecia With Endocrine Therapies in Patients With Cancer
- Significance of stress keratin expression in normal and diseased epithelia
- Effects of lifelong testosterone exposure on health and disease using Mendelian randomization
- Prostaglandin E <sub>2</sub> Receptor 2 Modulates Macrophage Activity for Cardiac Repair
- Drug repurposing: Clinical practices and regulatory pathways
- Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Advances in regenerative medicine-based approaches for skin regeneration and rejuvenation
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- New developments in the molecular treatment of ichthyosis: review of the literature
- Possible involvement of 5α-reduced neurosteroids in adrenergic and serotonergic stimulation of GFAP gene expression in rat C6 glioma cells
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis
- Prophylaxis and Management of Skin Toxicities